Business Wire

DELTA-Q-TECHNOLOGIES

2.5.2023 15:01:29 CEST | Business Wire | Press release

Share
Delta-Q Technologies Commences Full Production of its 3.3 kW Battery Charger

Delta-Q Technologies (Delta-Q), a leader in battery charging solutions for electric vehicles and industrial equipment, has announced that its innovative mid-power charger, the XV3300, is now in full-scale production. With its unique 3-in-1 design, this highly efficient charging system integrates a 3.3 kW battery charger, a 500 W DC-DC converter to power the vehicles’ auxiliary loads, and an EV charging station interface. These key features, encased in a ruggedized IP67 design, provide OEMs with an attractive package for simplifying electrification of their off-road applications.

“No other 3.3 kW charger on the market also includes a DC/DC converter for auxiliary DC loads and an EVSE charging interface in such a compact size,” said Mourad Chergui, Senior Product Manager with Delta-Q. “As we start full-scale production, we can begin to fulfill the substantial demand we received since we first announced the initial development.”

The 3.3 kW charging solution is available in 58.8, 65, and 120-volt DC models and is scalable, allowing OEMs to stack up to three chargers for power levels up to 10 kW. The XV3300 uses complex algorithms to deliver a precise charge to batteries of various chemistries and voltages, maximizing battery life and optimizing charge time.

Key features and benefits of the XV3300 charger include:

  • High Reliability: The XV3300 battery charger is compact, rugged, and IP67-rated. It is tested for automotive-grade shock and vibration. Its fully sealed aluminum die-cast enclosure protects the charger from dust, liquids, and the effects of immersion in up to one meter of water.
  • Enhanced Protection: The XV3300 is a low-voltage charger that optimally charges all battery chemistries and nominal voltages between 48 V to 120 V. It is also protected against short circuits, over-voltage, and over-temperature to ensure safe operation.
  • Flexible Power Options: The XV3300 is scalable and can be paralleled to provide between 3.3 kW to 10 kW of power for faster-charging options. The charger is also available as an on-board and off-board charger, providing OEMs with additional flexibility.
  • Integrated DC-DC converter: It provides auxiliary power to operate vehicle accessories such as air-conditioners, controllers, lights, turn signals, navigation, and communication devices. It also eliminates the need for an external DC-DC converter, saving OEMs and equipment operators space and cost.
  • EV Charging Station Interface: The XV3300 complies with SAE J1772 (levels 1 and 2) and IEC 61851 (modes 2 and 3) to charge from standard EVSE AC charging stations across North America and Europe. This feature provides end-users more charging options and greater vehicle flexibility.

To register for updates on the XV3300 battery charger or for specific details, including product specifications, visit https://connect.delta-q.com/xv3300.

About Delta-Q Technologies

Delta-Q Technologies is charging the future and driving the world’s transition to electric energy. We collaboratively design, test, and manufacture robust battery chargers that improve the performance of our customers’ electric drive vehicles and industrial machines. As the supplier of choice for Tier 1 OEMs, our customer support and engineering expertise guide our customers through the electrification process for a sustainable world.

Delta-Q is part of the ZAPI GROUP of companies and headquartered in Vancouver, Canada. The team and distribution span five continents to service industries such as electric golf cars, lift trucks, aerial work platforms, e-mobility, floor care machines, utility/recreational vehicles, and new markets, like construction and outdoor power equipment. Please visit www.delta-q.com or follow company updates on LinkedIn for more information.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

View source version on businesswire.com: https://www.businesswire.com/news/home/20230502005782/en/

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com
DK

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

2PointZero Group Signals Global Scale With Revenue Surge to AED 21.9 Billion and Net Profit of AED 7.7 Billion in H1 202631.7.2026 13:42:00 CEST | Press release

Group revenue growth supported by stable gross profit margin of 29%, and adjusted EBITDA of AED 5.0 billionGlobal expansion milestones include the completed sale of TAQA stake, and the acquisition of Traverse Midstream Partners in North America, Baobab Group in Africa, and 60.8% of ISEM in ItalyTIME ranks the Group 36th on the World’s Growth Leaders list for 2026, highlighting market stability, operational scale and disciplined approach to capital 2PointZero Group (ADX: 2POINTZERO), a leading Abu Dhabi-based investment holding firm, announced its financial results for the first half of 2026, reporting revenue of AED 21.9 billion and delivering a Group Net Profit of AED 7.7 billion. This robust performance is reflected in the Group’s adjusted EBITDA, which reached AED 5.0 billion after excluding fair value changes and one-offs. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260731538982/en/ Samia Bouazza, CEO of 2PointZero (P

Datroway® Approved in the EU as Only TROP2 Directed Medicine with Overall Survival Benefit for the First-Line Treatment of Patients with Metastatic TNBC Who Are Not Candidates for Immunotherapy31.7.2026 08:30:00 CEST | Press release

Approval based on TROPION-Breast02 phase 3 trial results where Daiichi Sankyo and AstraZeneca’s Datroway showed a statistically significant and clinically meaningful improvement for the dual primary endpoints of overall survival and progression-free survival Datroway now approved for two breast cancer indications in the EU Datroway® (datopotamab deruxtecan) has been approved in the European Union (EU) as monotherapy for the first-line treatment of adult patients with unresectable or metastatic triple negative breast cancer (TNBC) who are not candidates for PD-1/PD-L1 inhibitor therapy. Datroway is a specifically engineered TROP2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The approval by the European Commission follows the positive opinionof the Committee for Medicinal Products for Human Use of the European Medicines Agency and is based on result

Polpharma Biologics Announces FDA and EMA Acceptance for Review of PB016 Vedolizumab Biosimilar Candidate31.7.2026 08:30:00 CEST | Press release

Polpharma Biologics International AG today announces that the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) have accepted for review the Biologics License Application (BLA) and Marketing Authorisation Application (MAA), respectively, for PB016, a proposed vedolizumab biosimilar candidate to Takeda’s reference product Entyvio®* (vedolizumab) lyophilized vial for intravenous (IV) administration for the treatment of adults with moderately to severely active ulcerative colitis and Crohn's disease. The BLA and MAA acceptances represent significant milestones in Polpharma Biologics' development program and underscore the company's commitment to advancing high-quality biosimilars and expanding global access to affordable biologic medicines. "FDA and EMA acceptances for review of our IV vedolizumab biosimilar candidate mark a major achievement for Polpharma Biologics and validate our deep scientific expertise in biosimilar development and manufacturing," said

SES: Disclosure of Share Buyback Transactions31.7.2026 07:30:00 CEST | Press release

In the time period from June 2, 2026 until and including June 23, 2026, a number of 213,167 shares were bought back within the framework of the share buyback of SES to meet obligations under SES’s Equity Based Compensation Plan (EBCP). Shares were bought back as follows: Day of purchase Aggregated volume in shares Daily weighted average acquisition price of shares (EUR) Market June 2, 2026 27,097 8.8727 DXE June 2, 2026 72,903 8.8556 ENX June 5, 2026 16,624 8.3723 DXE June 5, 2026 31,510 8.4266 ENX June 15, 2026 26,451 7.8423 XPAR June 17, 2026 26,812 7.3910 XPAR June 23, 2026 11,770 7.2200 XPAR The transactions in a detailed form are published on SES’s website: https://www.ses.com/investors/shareholder-information/share-buy-backs. Follow us on: Twitter | Facebook | YouTube | LinkedIn | Instagram Read our Blogs > Visit the Media Gallery > About SES At SES, we believe that space has the power to make a difference. That’s why we design space solutions that help governments protect, busin

Half-Year Report on SES’s Liquidity Contract31.7.2026 07:30:00 CEST | Press release

Pursuant to the liquidity contract entered into by SES with BNP Paribas as of 7 April 2026, please see the below update on the progress of the liquidity services. When the liquidity services were implemented as of 7 April 2026, the following assets were in the liquidity account: € 2,500,000 As of 30 June 2026, the following assets appeared on the liquidity account: 228,186 shares; € 816,880. Over the period from 7 April 2026 to 30 June 2026, the following transactions were executed: 1,082 buy transactions; 1,308 sales transactions. Over this same period, the volumes traded represented: 1,093,335 shares and € 8,485,986 on the buy side; 873,399 shares and € 6,860,843 on the sell side. Follow us on: LinkedIn | Facebook | YouTube | X | Instagram Read our Blogs > Visit the Media Gallery > About SES At SES, we believe that space has the power to make a difference. That’s why we design space solutions that help governments protect, businesses grow, and people stay connected—no matter where th

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye